Cyclacel Pharmaceuticals, Inc. (CYCC)

Last Closing Price: 2.11 (2024-03-28)

Company Description

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.42M
Net Income (Most Recent Fiscal Year) $-22.56M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 2.72
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -6083.57%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -448.19%
Return on Assets (Trailing 12 Months) -151.29%
Current Ratio (Most Recent Fiscal Quarter) 0.91
Quick Ratio (Most Recent Fiscal Quarter) 0.91
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $0.72
Earnings per Share (Most Recent Fiscal Quarter) $-6.23
Earnings per Share (Most Recent Fiscal Year) $-26.75
Diluted Earnings per Share (Trailing 12 Months) $-27.22
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 0.84M
Free Float 0.77M
Market Capitalization $1.65M
Average Volume (Last 20 Days) 0.04M
Beta (Past 60 Months) 0.56
Percentage Held By Insiders (Latest Annual Proxy Report) 8.47%
Percentage Held By Institutions (Latest 13F Reports) 23.58%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%